Nathan A. Brooks

1.3k total citations
41 papers, 775 citations indexed

About

Nathan A. Brooks is a scholar working on Surgery, Urology and Molecular Biology. According to data from OpenAlex, Nathan A. Brooks has authored 41 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 10 papers in Urology and 8 papers in Molecular Biology. Recurrent topics in Nathan A. Brooks's work include Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (19 papers) and Urological Disorders and Treatments (9 papers). Nathan A. Brooks is often cited by papers focused on Bladder and Urothelial Cancer Treatments (21 papers), Urinary and Genital Oncology Studies (19 papers) and Urological Disorders and Treatments (9 papers). Nathan A. Brooks collaborates with scholars based in United States, Canada and Netherlands. Nathan A. Brooks's co-authors include Ashish M. Kamat, Trinity J. Bivalacqua, Kenneth G. Nepple, Chad R. Tracy, Michael A. O’Donnell, Sarah L. Mott, Lewis J. Thomas, Colin P. Dinney, Ryan L. Steinberg and Supriya Nagaraju and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer.

In The Last Decade

Nathan A. Brooks

38 papers receiving 763 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan A. Brooks United States	16	404	159	138	121	115	41	775
Łukasz Zapała Poland	15	234 0.6×	146 0.9×	68 0.5×	158 1.3×	91 0.8×	69	600
Luigi Cari Italy	16	133 0.3×	169 1.1×	268 1.9×	81 0.7×	17 0.1×	37	726
Felice Crocetto Italy	12	185 0.5×	188 1.2×	19 0.1×	156 1.3×	66 0.6×	41	570
Andrea Zitella Italy	17	262 0.6×	212 1.3×	25 0.2×	156 1.3×	77 0.7×	36	636
Minfeng Chen China	15	196 0.5×	326 2.1×	18 0.1×	214 1.8×	77 0.7×	46	743
Sara Zumerle Italy	8	78 0.2×	121 0.8×	85 0.6×	53 0.4×	15 0.1×	11	683
Sanjeev Madaan United Kingdom	15	270 0.7×	102 0.6×	13 0.1×	347 2.9×	257 2.2×	69	861
H Kameoka Japan	13	116 0.3×	120 0.8×	54 0.4×	51 0.4×	44 0.4×	64	506
Balan Louis Gaspar India	10	73 0.2×	140 0.9×	72 0.5×	55 0.5×	26 0.2×	32	602

Countries citing papers authored by Nathan A. Brooks

Since Specialization

Citations

This map shows the geographic impact of Nathan A. Brooks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan A. Brooks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan A. Brooks more than expected).

Fields of papers citing papers by Nathan A. Brooks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan A. Brooks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan A. Brooks. The network helps show where Nathan A. Brooks may publish in the future.

Co-authorship network of co-authors of Nathan A. Brooks

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan A. Brooks. A scholar is included among the top collaborators of Nathan A. Brooks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan A. Brooks. Nathan A. Brooks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Janice Y., Nathan A. Brooks, Brandon Antonakos, et al.. (2024). Abstract 3230: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers. Cancer Research. 84(6_Supplement). 3230–3230. 1 indexed citations

Lee, Janice Y., Nathan A. Brooks, Brandon Antonakos, et al.. (2024). Abstract PR015: Discovery of LY4050784 (FHD-909), a selective BRM (SMARCA2) ATPase inhibitor for the treatment of BRG1(SMARCA4) mutant cancers. Molecular Cancer Therapeutics. 23(6_Supplement). PR015–PR015. 1 indexed citations

Matulay, Justin T., Roger Li, Patrick J. Hensley, et al.. (2021). Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. The Journal of Urology. 205(6). 1612–1621. 42 indexed citations

Hensley, Patrick J., Kelly K. Bree, Nathan A. Brooks, et al.. (2021). Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. British Journal of Urology. 128(5). 634–641. 8 indexed citations

Kokorovic, Andrea, Mary E. Westerman, Kate J. Krause, et al.. (2021). Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer. 7(2). 243–252. 3 indexed citations

Lobo, Niyati, Nathan A. Brooks, Alexandre R. Zlotta, et al.. (2021). 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology. 18(10). 611–622. 104 indexed citations

Bree, Kelly K., Patrick J. Hensley, Nathan A. Brooks, et al.. (2021). Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World Journal of Urology. 39(11). 4143–4149. 5 indexed citations

Steinberg, Ryan L., Vignesh T. Packiam, Lewis J. Thomas, et al.. (2021). Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic Oncology Seminars and Original Investigations. 40(1). 9.e1–9.e7. 19 indexed citations

Brooks, Nathan A., et al.. (2021). The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning. Scientific Reports. 11(1). 774–774. 26 indexed citations

10.

Bree, Kelly K., Patrick J. Hensley, Nathan A. Brooks, et al.. (2021). MP48-14 UTUC SURVEILLANCE FOLLOWING BCG-TREATED NMIBC: TIMING AND RISK FACTORS ASSOCIATED WITH RECURRENCE. The Journal of Urology. 206(Supplement 3).

11.

Bree, Kelly K., Patrick J. Hensley, Nathan A. Brooks, et al.. (2021). Impact of upper tract urothelial carcinoma on response to BCG in patients with non‐muscle‐invasive bladder cancer. British Journal of Urology. 128(5). 568–574. 3 indexed citations

12.

Brooks, Nathan A., Supriya Nagaraju, Justin T. Matulay, Xiang-Yang Han, & Ashish M. Kamat. (2020). Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. European Urology Oncology. 4(5). 826–828. 7 indexed citations

13.

Brooks, Nathan A. & Michael A. O’Donnell. (2019). Combination Intravesical Therapy. Urologic Clinics of North America. 47(1). 83–91. 6 indexed citations

14.

Tracy, Chad R., et al.. (2018). Increasing the size of ureteral access sheath during retrograde intrarenal surgery improves surgical efficiency without increasing complications. World Journal of Urology. 36(6). 971–978. 26 indexed citations

15.

Brooks, Nathan A., et al.. (2018). Pilot Study to Determine Optimal Stent Duration Following Ureteroscopy: Three versus Seven days. Current Urology. 11(2). 97–102. 15 indexed citations

16.

Brooks, Nathan A., et al.. (2017). Testosterone Therapy: Review of Clinical Applications.. PubMed. 96(7). 441–449. 40 indexed citations

17.

Brooks, Nathan A., Hagai Tavori, Jessica Minnier, et al.. (2017). Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. Journal of clinical lipidology. 11(3). 667–673. 35 indexed citations

18.

Steinberg, Ryan L., Nathan A. Brooks, Lewis J. Thomas, Sarah L. Mott, & Michael A. O’Donnell. (2016). Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non–muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 35(5). 201–207. 10 indexed citations

19.

Wang, Zhigang, William Watt, Nathan A. Brooks, et al.. (2010). Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1804(9). 1817–1831. 52 indexed citations

20.

Staschke, Kirk A., Sucai Dong, J. K. Saha, et al.. (2009). IRAK4 Kinase Activity Is Required for Th17 Differentiation and Th17-Mediated Disease. The Journal of Immunology. 183(1). 568–577. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact